Opendata, web and dolomites

20SInhibitor SIGNED

Selective 20S proteasome inhibition for multiple myeloma therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 20SInhibitor project word cloud

Explore the words cloud of the 20SInhibitor project. It provides you a very rough idea of what is the project "20SInhibitor" about.

inhibiting    structural    probability    industry    chance    attractive    drugs    family    regulators    risk    20s    revisit    protection    equip    pis    peptide    light    minimize    designed    plasma    laboratory    strategy    toxicity    inhibit    actions    therapeutic    lymphoma    direction    intervention    commercialization    first    treatment    therapy    perspective    networks    chymotrypsin    multiple    lower    position    basis    peptidomimetic    cancer    inhibitors    cells    preliminary    therapeutics    anticipate    ip    molecules    myeloma    initial    protein    20    innovation    small    sufficient    pharmaceutical    motif    later    termed    carry    blood    specificity    mm    compounds    regulatory    mainstay    deleterious    core    form    drug    synthetic    cell    regimens    incurable    mcl    sequence    26s    switched    selectively    50    selective    peptides    companies    ccrs    reduce    proteins    catalytic    mantle    business    proteasomes    pose    receiving    contacts    revealed    artificial    approval    proteasome   

Project "20SInhibitor" data sheet

The following table provides information about the project.

Coordinator
WEIZMANN INSTITUTE OF SCIENCE 

Organization address
address: HERZL STREET 234
city: REHOVOT
postcode: 7610001
website: www.weizmann.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00

Map

 Project objective

Multiple myeloma (MM) is a cancer of plasma cells, that is incurable, and the second most common form of blood cancer. Proteasome inhibitors (PIs) are considered a mainstay in the treatment of MM and mantle cell lymphoma (MCL). Current drugs, based on PIs however, target the chymotrypsin-like activity of the 20S proteasome, and inhibit the activities of both the 20S and 26S proteasomes. Thus, it is possible that selective drug intervention specifically inhibiting only the 20S proteasomes will reduce toxicity, and minimize the deleterious side effects of the current therapeutic regimens.

Our preliminary work revealed a family of 20S proteasome inhibitors, which we termed Catalytic Core Regulators (CCRs) that selectively target the 20S proteasome rather than the 26S complex. Based on sequence motif and structural elements of the CCRs we have designed an artificial protein that is capable of inhibiting the 20S proteasome. We anticipate that these findings will lead to the design of synthetic proteins, peptides or peptidomimetic compounds targeting cancer cells more specifically. This specificity will pose the compounds in an attractive light for using them in various therapeutic applications.

What is exciting from the commercialization perspective, is that pharmaceutical research has switched to revisit the use of peptides as therapeutics. Pharmaceutical companies have seen the development of peptides as a promising direction to lower their risk position. Overall, peptide therapeutics have a 20% chance of receiving regulatory approval, a probability that is 50% higher than that for the approval of small molecules, which form the basis of so called traditional drugs.

In the project, we will carry out actions, which will equip us with the sufficient IP protection strategy, business strategy, industry networks and initial contacts for taking the innovation out from the laboratory to next phase in developing therapy first for MM and MCL later on.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "20SINHIBITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "20SINHIBITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EffectiveTG (2018)

Effective Methods in Tame Geometry and Applications in Arithmetic and Dynamics

Read More  

E-DIRECT (2020)

Evolution of Direct Reciprocity in Complex Environments

Read More  

Growth regulation (2019)

The wide-spread bacterial toxin delivery systems and their role in multicellularity

Read More